ethyl 2-(4-propionylphenoxy)acetate | 51828-70-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: ethyl 2-(4-propionylphenoxy)acetate
• 英文别名: ethyl 2-(4-propanoylphenoxy)acetate
• CAS: 51828-70-7
• 化学式: C₁₃H₁₆O₄
• mdl: MFCD09931656
• 分子量: 236.268
• InChiKey: HGVABXWMWFXRAO-UHFFFAOYSA-N

物化性质

• 熔点：
  31-32 °C(Solv: chloroform (67-66-3))
• 沸点：
  356.9±17.0 °C(Predicted)
• 密度：
  1.101±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.384
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 2-(4-propionylphenoxy)acetate 在 盐酸羟胺 、 sodium acetate 、 caesium carbonate 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 19.0h， 生成 (E)-ethyl 2-(4-(1-(((5-methyl-2-phenyloxazol-4-yl)methoxy)imino)propyl)phenoxy)acetate
  参考文献：
  名称：

  Effect of structurally constrained oxime–ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists

  摘要：

  A novel series of thaizole and oxazole containing phenoxy acetic acid derivatives is reported as PPAR-pan agonists. Incorporation of structurally constrained oxime-ether based linker in the chemotype of a potent PPAR delta selective agonist GW-501516 was adapted as designing strategy. In vitro, selected test compounds 12a, 12c, 17a and 18a showed PPAR-pan agonists activities and among these four compounds tested, 12a emerged as highly potent and efficacious compound, while 17a exhibited moderate and balanced PPAR-pan agonistic activity. In vivo, selected test compounds 12a and 17a exhibited significant anti-hyperglycemic and anti-hyperlipidemic activities in relevant animal models. These results support our hypothesis that the introduction of structurally constrained oxime-ether linker between lipophilic tail and acidic head plays an important role in modulating subtype selectivity and subsequently led to the discovery of potent PPAR-pan agonists. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.12.023
• 作为产物：
  描述：

  苯丙酸去甲睾酮 在 aluminum (III) chloride 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 生成 ethyl 2-(4-propionylphenoxy)acetate
  参考文献：
  名称：

  Effect of structurally constrained oxime–ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists

  摘要：

  A novel series of thaizole and oxazole containing phenoxy acetic acid derivatives is reported as PPAR-pan agonists. Incorporation of structurally constrained oxime-ether based linker in the chemotype of a potent PPAR delta selective agonist GW-501516 was adapted as designing strategy. In vitro, selected test compounds 12a, 12c, 17a and 18a showed PPAR-pan agonists activities and among these four compounds tested, 12a emerged as highly potent and efficacious compound, while 17a exhibited moderate and balanced PPAR-pan agonistic activity. In vivo, selected test compounds 12a and 17a exhibited significant anti-hyperglycemic and anti-hyperlipidemic activities in relevant animal models. These results support our hypothesis that the introduction of structurally constrained oxime-ether linker between lipophilic tail and acidic head plays an important role in modulating subtype selectivity and subsequently led to the discovery of potent PPAR-pan agonists. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.12.023

文献信息

• HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA
  申请人：Pingali Harikishore

  公开号：US20130281366A1

  公开（公告）日：2013-10-24

  The present invention relates to compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation. The present invention is directed towards compounds which can be used to treat diseases such as Hyperlipidemia and also have a beneficial effect on cholesterol.

  本发明涉及一般式（I）的化合物，它们的互变异构体、立体异构体、药学上可接受的盐、含有它们的药物组合物、其制备方法、这些化合物在医学上的应用以及其制备中涉及的中间体。 本发明针对可用于治疗高脂血症等疾病并对胆固醇产生有益影响的化合物。
• Ethacrynic acid as a lead structure for the development of potent urease inhibitors
  作者：Ingo Janser、Caitlyn M. Vortolomei、Ranjith K. Meka、Courtney A. Walsh、Romy F.J. Janser

  DOI：10.1016/j.crci.2013.03.020

  日期：2013.7

  Résumé Ethacrynic acid and a series of its analogues were synthesized and subsequently evaluated for their inhibitory effect on jack bean urease. Ethacrynic acid showed, even at low concentrations, very potent inhibitory activity against the enzyme. For ethacrynic acid, the inhibition potential increased with increasing preincubation time of ethacrynic acid and enzyme, whereas for some other compounds a higher preincubation time lead to a significant reduction of their activity. We could demonstrate that the α,β-unsaturated carbonyl unit of our compounds is mandatory to inhibit the enzyme, possibly due to its ability to bind to cysteine residues in the active site of the jack bean urease.

  摘要 合成了乙烯酰基酸及其一系列类化合物，并随后评估了它们对豌豆尿素酶的抑制作用。乙烯酰基酸即使在低浓度下也显示出对该酶非常强的抑制活性。对于乙烯酰基酸，抑制潜力随着乙烯酰基酸和酶的预孵育时间的增加而增强，然而对于其他一些化合物，较长的预孵育时间会显著降低其活性。我们证明了我们化合物中的α,β-不饱和羰基单元对抑制该酶是必不可少的，可能是由于它能够与豌豆尿素酶活性位点中的半胱氨酸残基结合。
• Chemical Compounds
  申请人：Katamreddy Subba Reddy

  公开号：US20080234199A1

  公开（公告）日：2008-09-25

  Triphenylethylene compounds of formula (I) are provided. The compounds are particularly useful for selective estrogen receptor modulation.

  提供了公式(I)的三苯乙烯化合物。这些化合物对于选择性雌激素受体调节非常有用。
• Heterocyclic compounds suitable for the treatment of dyslipidemia
  申请人：Pingali Harikishore

  公开号：US08822414B2

  公开（公告）日：2014-09-02

  The present invention relates to compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation. The present invention is directed towards compounds which can be used to treat diseases such as Hyperlipidemia and also have a beneficial effect on cholesterol.

  本发明涉及一般式（I）的化合物，它们的互变异构体，立体异构体，它们的药学上可接受的盐，含有它们的药物组成物，制备它们的方法，这些化合物在医学上的应用以及用于它们制备的中间体。本发明针对的是可用于治疗高脂血症等疾病并对胆固醇有益的化合物。
• WO2007/62148
  申请人：——

  公开号：——

  公开（公告）日：——